KEMIFARMA Consulting ApS: Financial statements 2021
CVR: 34709955
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
KEMIFARMA Consulting ApS (CVR 34709955) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -122,398 and a net result of DKK 410,239 compared with DKK 392,334 the year before. Equity in the 2021 report amounted to DKK 3,149,061. The solvency ratio was 99.4%.
- Gross Profit
- DKK -122,398
- Profit/Loss
- DKK 410,239
- Equity
- DKK 3,149,061
- Total Assets
- DKK 3,168,012
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -122K | 410K | 3.1M | - |
| 2020 | - | -15K | 392K | 2.8M | - |
| 2019 | - | -32K | 176K | 2.4M | - |
| 2018 | - | -23K | -79K | 2.3M | - |
| 2017 | - | -11K | 191K | 2.4M | - |
Official annual report
Find more companies like KEMIFARMA Consulting ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
KEMIFARMA Consulting ApS has published its annual report for 2020. Gross profit came to DKK -14,663, and the net result was DKK 392,334.
About KEMIFARMA Consulting ApS
KEMIFARMA Consulting ApS is a Danish company of the type Anpartsselskab based in Kgs. Lyngby, founded in 2012. The company is registered under the industry Anden teknisk rådgivning. The company was previously named KEMIFARMA HOLDING ApS. The management consists of Christian Hede-Andersen. The company is owned by Christian Hede-Andersen. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK -57,469 and a net result of DKK 541,385 compared with DKK -378,700 the year before. Equity in the 2025 report amounted to DKK 3,414,022.
